- Home>
- Specialties>
- Oncology and Hematology>
- Metastasis
Search for Metastasis in Oncology and Hematology
Physician-authored summaries on the latest research on metastasis, editorials on metastasis, and perspectives on metastasis - drawn from the top medical journals.
Sort by:
Items 1 to 20 of 52 results - Relevance
- Date
You searched for: metastasis in Oncology and Hematology
-
Markers of Risk for Bone Metastases in Breast Cancer
- October 11, 2011
- William J. Gradishar, MD
- Oncology and Hematology
Higher serum beta C-terminal telopeptide levels predicted shorter relapse-free survival in women with bone-only metastases.- Reviewing:
- Lipton A et al., J Clin Oncol 2011 Sep 20; 29:3605. Korde LA and Gralow JR., J Clin Oncol 2011 Sep 20; 29:3600.
-
Occult Metastases in Breast Cancer Do Not Affect Survival Substantially
- August 16, 2011
- Abigail S. Caudle, MD, and Henry Mark Kuerer, MD, PhD, FACS
- Oncology and Hematology
Routine detection of occult sentinel node and bone marrow micrometastases is not clinically indicated for early breast cancer.- Reviewing:
- Giuliano AE et al., JAMA 2011 Jul 27; 306:385. Merkow RP and Ko CY., JAMA 2011 Jul 27; 306:436.
-
Denosumab for Bone Metastases from Advanced Prostate Cancer
- April 5, 2011
- Robert Dreicer, MD, MS, FACP
- Oncology and Hematology
Denosumab was superior to zoledronic acid in preventing skeletal-related events.- Reviewing:
- Fizazi K et al., Lancet 2011 Mar 5; 377:813.
-
Is Bevacizumab Safe for Patients with Brain Metastases?
- February 23, 2010
- Robert Dreicer, MD, MS, FACP
- Oncology and Hematology
Bevacizumab did not appear to raise risk for cerebral hemorrhage substantially in these patients.- Reviewing:
- Besse B et al., Clin Cancer Res 2010 Jan 1; 16:269.
-
Clodronate for Prostate Cancer: An Update
- September 22, 2009
- Robert Dreicer, MD, MS, FACP
- Oncology and Hematology
Long-term results revealed an overall survival benefit for men with metastatic, but not locally advanced, disease.- Reviewing:
- Dearnaley DP et al., Lancet Oncol 2009 Sep; 10:872.
-
Lymph Node Biopsy in Older Patients with Breast Cancer
- April 14, 2009
- Henry Mark Kuerer, MD, PhD, FACS
- Oncology and Hematology
A clinical model identifies low-risk patients who could be spared such evaluations.- Reviewing:
- Chagpar AB et al., Ann Surg 2009 Mar; 249:455.
-
Bisphosphonates for Nonmetastatic Prostate Cancer? Free
- June 11, 2007
- Robert Dreicer, MD, MS, FACP
- Oncology and Hematology
Clodronate did not improve bone-metastasis–free survival or overall survival in patients with nonmetastatic prostate cancer.- Reviewing:
- Mason MD et al., J Natl Cancer Inst 2007 May 16; 99:765-76.
-
Is Axillary Dissection Necessary in Breast Cancer Patients with Positive Sentinel Lymph Nodes? Free
- February 9, 2011
- Henry Mark Kuerer, MD, PhD, FACS
- Oncology and Hematology
Overall survival and disease-free survival were not inferior in patients with SLN metastases who did not undergo axillary dissection.- Reviewing:
- Giuliano AE et al., JAMA 2011 Feb 9; 305:569. Carlson GW and Wood WC., JAMA 2011 Feb 9; 305:606.
-
Will Axillary Radiotherapy Replace Axillary Dissection in Women with Positive Sentinel Nodes?
- November 29, 2011
- Henry Mark Kuerer, MD, PhD, FACS
- Oncology and Hematology
For management of early breast cancer, sufficiency of local therapy must be balanced against risk for overtreatment.- Reviewing:
- Haffty BG et al., J Clin Oncol 2011 Oct 31;:
-
Are Chemotherapy Holidays an Option in Advanced Colorectal Cancer?
- August 16, 2011
- David H. Ilson, MD, PhD
- Oncology and Hematology
Intermittent therapy — although not noninferior to continuous chemotherapy in terms of overall survival — could remain an option for appropriately selected patients.- Reviewing:
- Adams RA et al., Lancet Oncol 2011 Jul; 12:642.
-
ASCO 2011 Report: Gastrointestinal Cancer
- July 19, 2011
- David H. Ilson, MD, PhD
- Oncology and Hematology
Key trials focused on new therapies for colorectal, anal, gastric, and hepatocellular cancers. -
When Biology Bests Clinical Assumptions About Breast Cancer
- June 14, 2011
- William J. Gradishar, MD
- Oncology and Hematology
Tumor biology is a critically important factor that must be integrated into the determination of prognosis.- Reviewing:
- Wo JY et al., J Clin Oncol 2011 May 23;: Hernandez-Aya LF et al., J Clin Oncol 2011 May 23;:
-
Chemotherapy for Older Patients with Metastatic Colorectal Cancer
- June 7, 2011
- David H. Ilson, MD, PhD
- Oncology and Hematology
Older patients experienced limited added benefit from reduced-dose oxaliplatin or capecitabine.- Reviewing:
- Seymour MT et al., Lancet 2011 May 21; 377:1749.
-
FOLFIRINOX Beats Gemcitabine for Metastatic Pancreatic Cancer Free
- May 11, 2011
- David H. Ilson, MD, PhD
- Oncology and Hematology
In a landmark trial, combination chemotherapy with oxaliplatin, irinotecan, fluorouracil, and leucovorin was superior to gemcitabine in all outcome measures.- Reviewing:
- Conroy T et al., N Engl J Med 2011 May 12; 364:1817.
-
Detecting Occult Sentinel Node Metastases: More Information Is Not Always Better
- March 8, 2011
- William J. Gradishar, MD
- Oncology and Hematology
Breast cancer survival at 5 years was largely unaffected by occult metastases.- Reviewing:
- Weaver DL et al., N Engl J Med 2011 Feb 3; 364:412.
-
ASCO 2010 Report: Gastrointestinal Cancer Free
- July 13, 2010
- David H. Ilson, MD, PhD
- Oncology and Hematology
Genetic predictors of treatment outcomes; results from new drug trials -
ASCO 2010 Report: Genitourinary Cancer
- July 13, 2010
- Robert Dreicer, MD, MS, FACP
- Oncology and Hematology
Trial results of new treatments for prostate and renal cancers -
Combination Targeted Therapy for Patients with Advanced Renal Cancer
Bevacizumab plus everolimus was tolerated by most patients, but this combination might not be more effective than single-agent targeted therapy.- Reviewing:
- Hainsworth JD et al., J Clin Oncol 2010 May 1; 28:2131.
-
Prognostic Factors in Patients with Advanced Urothelial Cancer Who Receive Salvage Therapy
- April 20, 2010
- Robert Dreicer, MD, MS, FACP
- Oncology and Hematology
Performance status, presence of liver metastases, and hemoglobin levels help predict survival in the second-line treatment setting.- Reviewing:
- Bellmunt J et al., J Clin Oncol 2010 Apr 10; 28:1850.
-
Does Preoperative Magnetic Resonance Imaging Lower Reoperation Rates in Breast Cancer Patients? Free
- April 13, 2010
- Isabelle Bedrosian, MD, FACS
- Oncology and Hematology
Reoperation rates were similar regardless of preoperative MRI assessment.- Reviewing:
- Turnbull L et al., Lancet 2010 Feb 13; 375:563. Morris EA., Lancet 2010 Feb 13; 375:528.
Sort by:
Items 1 to 20 of 52 results - Relevance
- Date
